GEN Exclusives

More »

GEN News Highlights

Back to Item »

Cell Therapeutics Pays $30M in Cash and Stock for S*BIO’s Selective JAK2 Inhibitor

Access to mid-stage candidate for myelofibrosis bolsters CTI’s pipeline for blood-related disorders.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Value-Pricing Cancer Drugs

Do you think all new cancer drugs awaiting approval should undergo value-pricing?

More »